TW200731975A - Novel combinations of medicaments for the treatment of respiratory diseases - Google Patents

Novel combinations of medicaments for the treatment of respiratory diseases

Info

Publication number
TW200731975A
TW200731975A TW095137032A TW95137032A TW200731975A TW 200731975 A TW200731975 A TW 200731975A TW 095137032 A TW095137032 A TW 095137032A TW 95137032 A TW95137032 A TW 95137032A TW 200731975 A TW200731975 A TW 200731975A
Authority
TW
Taiwan
Prior art keywords
medicaments
treatment
respiratory diseases
novel combinations
combinations
Prior art date
Application number
TW095137032A
Other languages
English (en)
Other versions
TWI396541B (zh
Inventor
Thierry Bouyssou
Michael P Pieper
Andreas Schnapp
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35658907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200731975(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200731975A publication Critical patent/TW200731975A/zh
Application granted granted Critical
Publication of TWI396541B publication Critical patent/TWI396541B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
TW095137032A 2005-10-10 2006-10-05 用於治療呼吸疾病之新穎藥物組合 TWI396541B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05109374 2005-10-10

Publications (2)

Publication Number Publication Date
TW200731975A true TW200731975A (en) 2007-09-01
TWI396541B TWI396541B (zh) 2013-05-21

Family

ID=35658907

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095137032A TWI396541B (zh) 2005-10-10 2006-10-05 用於治療呼吸疾病之新穎藥物組合

Country Status (23)

Country Link
US (10) US20070086957A1 (zh)
EP (1) EP1940409B1 (zh)
JP (1) JP5081158B2 (zh)
KR (1) KR101344225B1 (zh)
CN (1) CN101282729A (zh)
AR (1) AR057148A1 (zh)
AT (1) ATE482709T1 (zh)
AU (1) AU2006301329B9 (zh)
BR (1) BRPI0617269A2 (zh)
CA (1) CA2624584C (zh)
CY (1) CY1111022T1 (zh)
DE (1) DE502006007982D1 (zh)
DK (1) DK1940409T3 (zh)
ES (1) ES2353404T3 (zh)
IL (1) IL190652A (zh)
NZ (1) NZ567547A (zh)
PL (1) PL1940409T3 (zh)
PT (1) PT1940409E (zh)
RU (1) RU2436578C2 (zh)
SI (1) SI1940409T1 (zh)
TW (1) TWI396541B (zh)
WO (1) WO2007042467A1 (zh)
ZA (1) ZA200801667B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US20070088160A1 (en) * 2005-08-15 2007-04-19 Thomas Krueger Process for the manufacturing of betamimetics
PL2413902T3 (pl) 2009-03-18 2020-01-31 Incarda Therapeutics, Inc. Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬
GB2581301A (en) 2016-02-01 2020-08-12 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy to manage atrial arrhythmias including atrial fibrillation
US20200069679A1 (en) * 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
CN110869018A (zh) 2017-05-10 2020-03-06 英凯达治疗公司 通过肺部施用治疗心脏病况的单位剂量、气雾剂、试剂盒和方法
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US20210322309A1 (en) * 2020-04-16 2021-10-21 Cai Gu Huang Inhalable Formulation of a Solution Containing Olodaterol

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
DE69324161T2 (de) * 1992-12-09 1999-10-28 Boehringer Ingelheim Pharma Stabilisierte medizinische aerosollösungen
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
AU721566B2 (en) * 1995-06-27 2000-07-06 Boehringer Ingelheim Kg New stable pharmaceutical preparation for producing propellant-free aerosols
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
PL365694A1 (en) * 2000-06-28 2005-01-10 Teva Pharmaceutical Industries Ltd. Carvedilol
ES2228965T3 (es) 2000-10-12 2005-04-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Monohidrato cristalino de bromuro de tiotropio, procedimiento para su preparacion y su uso para la produccion de un medicamento.
US20020111363A1 (en) * 2000-10-31 2002-08-15 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
CN100586948C (zh) 2001-06-22 2010-02-03 贝林格尔英格海姆法玛两合公司 结晶性抗胆碱能药,其制备方法及其在药物制备中的用途
DE10212264A1 (de) * 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US7244728B2 (en) * 2004-03-17 2007-07-17 Boehringer Ingelheim International Gmbh Long acting betamimetics for the treatment of respiratory diseases
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
PT1781298E (pt) 2004-04-22 2012-02-03 Boehringer Ingelheim Int Combinações farmacêuticas contendo benzoxazinas para o tratamento de doenças respiratórias
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists

Also Published As

Publication number Publication date
CY1111022T1 (el) 2015-06-11
IL190652A (en) 2013-10-31
RU2436578C2 (ru) 2011-12-20
ZA200801667B (en) 2009-03-25
NZ567547A (en) 2011-06-30
JP2009511541A (ja) 2009-03-19
CN101282729A (zh) 2008-10-08
US20150086489A1 (en) 2015-03-26
US20130189194A1 (en) 2013-07-25
US20070086957A1 (en) 2007-04-19
WO2007042467A1 (de) 2007-04-19
KR101344225B1 (ko) 2013-12-23
ES2353404T3 (es) 2011-03-01
AU2006301329A1 (en) 2007-04-19
US20170128455A1 (en) 2017-05-11
DK1940409T3 (da) 2010-11-29
US20110135582A1 (en) 2011-06-09
US20120263655A1 (en) 2012-10-18
US20160287600A1 (en) 2016-10-06
AR057148A1 (es) 2007-11-21
US20140056823A1 (en) 2014-02-27
CA2624584A1 (en) 2007-04-19
RU2008117834A (ru) 2010-01-27
AU2006301329B9 (en) 2012-09-06
ATE482709T1 (de) 2010-10-15
EP1940409A1 (de) 2008-07-09
TWI396541B (zh) 2013-05-21
EP1940409B1 (de) 2010-09-29
AU2006301329B2 (en) 2012-08-02
JP5081158B2 (ja) 2012-11-21
CA2624584C (en) 2017-01-03
US20140286879A1 (en) 2014-09-25
PL1940409T3 (pl) 2011-03-31
PT1940409E (pt) 2010-12-03
DE502006007982D1 (de) 2010-11-11
BRPI0617269A2 (pt) 2011-07-19
IL190652A0 (en) 2008-12-29
SI1940409T1 (sl) 2010-12-31
KR20080067643A (ko) 2008-07-21
US20170340645A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
GEP20125565B (en) Lactam compounds and their pharmaceutical use
MX2007008924A (es) Compuestos quimicos.
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
TW200621259A (en) Chemical compounds
MY148945A (en) Combination of a betamimetic with anticholinergics and/or steroids
TW200640908A (en) Chemical compounds
TW200738659A (en) Novel compounds
TW200736234A (en) Chemical compounds
TW200801003A (en) Novel compounds
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
GB0625648D0 (en) Compounds
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
MX2009004908A (es) Compuestos quimicos.
TW200833670A (en) Novel compounds 569
TW200626553A (en) Novel compounds
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
TW200607508A (en) Powder formulations for inhalation, comprising enantiomerically pure beta agonists